NCT02497027

Pharmacogenetic Testing in an Outpatient Population of Patients With Depression

Pharmacogenetic Testing in an Outpatient Population of Patients With Major Depressive Disorder or Depressive Disorder Not Otherwise Specified

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 83 (actual)
• Sponsor: Avera McKennan Hospital & University Health Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, control group design of pharmacogenetic implementation in a mental health population of subjects taking anti-depressants and/or anti-psychotics with a new or current primary or secondary diagnosis of Major Depressive Disorder (MDD) or Depressive Disorder Not Otherwise Specified (DDNOS).

Detailed description

This is a randomized, control group design of pharmacogenetic implementation in a mental health population of subjects taking anti-depressants and/or anti-psychotics with a new or current primary or secondary diagnosis of Major Depressive Disorder (MDD) or Depressive Disorder Not Otherwise Specified (DDNOS). Prospective data will be collected on all subjects until study completion at 24-25 weeks post enrollment. Claims data may be reviewed per pay, if such data are readily available in a timely manner.

Conditions

• Depression

Interventions

Type	Name	Description
OTHER	pharmacogenetic testing	pharmacogenetic testing report released to physician at 4 weeks post enrollment
OTHER	pharmacogenetic testing	pharmacogenetic testing report released to physician at 12 weeks post enrollment

Timeline

• Start date: 2015-02-01
• Primary completion: 2017-04-01
• Completion: 2017-04-01
• First posted: 2015-07-14
• Last updated: 2017-05-03

Locations

1 site across 1 country: United States